Anavex Life Sciences Corp (AVXL)

[crescentmotor]

So all this fuss about single trial, low n, and the missed irrelevant ADL endpoint seems more like a continuing sandbox tantrum than a serious argument.

That's because Investor2014 and Doc328 only have those nuanced crumbs and details left in their worthless attack arsenal. Even the transient dizziness adverse effect has evaporated as a meaningful concern. Neither one posts with a global perspective because that sort of big picture evaluation easily establishes that Blarcamesine is head and shoulders better, from both an efficacy and side effects perspective, than the current Mab offerings. The recent peer review article offers vigorous support for Blarcamesine and the MAA is under active review. Nit picking bashers will soon be relegated to the curb where they belong--the big picture is now in focus.